Fidaxomicin
Based on 7 publication(s) in Google Scholar
Fidaxomicin (OPT-80), a macrocyclic antibiotic, is an orally active and potent RNA polymerase inhibitor. Fidaxomicin has a narrow spectrum of antibacterial activity and a good anti-Clostridium difficile activity (MIC90=0.12 μg/mL). Fidaxomicin can be used for Clostridium difficile infection (CDI) research.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.77%
- No. CAS: 873857-62-6
- Fòrmula: C52H74Cl2O18
- Peso molecular:1058.04
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Fidaxomicin
More- Cell Host Microbe. 2023 May 10;31(5):734-750.e8. [Abstract]
- Gut Microbes. 2024 Jan-Dec;16(1):2342583. [Abstract]
- BMC Med. 2020 Jul 31;18(1):204. [Abstract]
- Eur J Med Chem. 2023 Oct 5:258:115620. [Abstract]
- Molecules. 2023 Dec 17;28(24):8142. [Abstract]
- Viruses. 2023 Sep 4;15(9):1872. [Abstract]
- Virology. 2026 Sep:622:110972. [Abstract]
-
WB
Ver todos los productos específicos de isoformas DNA/RNA Synthesis
MoreVer todos los productos específicos de isoformas Antibiotic
More
Actividad biológica
|
RNA Polymerase |
Fidaxomicin selectively eradicates pathogenic Clostridium difficile with minimal disruption to the multiple species of bacteria that make up the normal, healthy intestinal flora[1].
Fidaxomicin is not inhibitory to commonly cultured bowel commensals (MIC90 >1024 μg/mL)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Golden Syrian hamsters (80-100 g, Hamster model for pseudomembranous colitis)[3]
-
Dosage:0.2, 1, and 5 mg/kg
-
Administration:Orally, once a day for 5 days, beginning 8 h after infection
-
Result:Completely prevented the lethality of the animals. Completely prevented the development of antibiotic-induced C. difficile colitis in hamsters at doses as low as 0.2 mg/kg.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 873857-62-6
-
Appearance Solid
-
Peso molecular 1058.04
-
Fòrmula C52H74Cl2O18
-
Color White to off-white
-
SMILES
O=C(C(C(O)=C(Cl)C(O)=C1Cl)=C1CC)O[C@H]([C@H](O[C@H]2OC/C(C(O[C@](C/C=C3C)([H])[C@H](O)C)=O)=C\C=C\C[C@@H](/C(C)=C\[C@H](CC)[C@@H](O[C@@](OC(C)(C)[C@@H](OC(C(C)C)=O)[C@@H]4O)([H])[C@H]4O)\C(C)=C/3)O)C)[C@@H]([C@@H]2OC)O
-
Synonyms
OPT-80; PAR-101
-
Structure Classification
-
Initial Source
Clostridium difficile
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Cell Host Microbe
The natural product chlorotonil A preserves colonization resistance and prevents relapsing Clostridioides difficile infection. [Abstract]2023 May 10;31(5):734-750.e8. PMID: 37098342 -
Gut Microbes
Comparison of fidaxomicin, thuricin CD, vancomycin and nisin highlights the narrow spectrum nature of thuricin CD. [Abstract]2024 Jan-Dec;16(1):2342583. PMID: 38722061 -
BMC Med
Antibiotic fidaxomicin is an RdRp inhibitor as a potential new therapeutic agent against Zika virus. [Abstract]2020 Jul 31;18(1):204. PMID: 32731873
Fidaxomicin purchased from MedChemExpress. Usage Cited in: BMC Med. 2020 Jul 31;18(1):204. [Abstract]
Western blotting analysis of protein expression of ZIKV NS3 in the cell lysates of SNB19 for the anti-ZIKV activity of fidaxomicin at indicated hpi. Fidaxomicin blocks ZIKV infection in vitro.
-
Eur J Med Chem
Design, synthesis, and biological evaluation of a series of new anthraquinone derivatives as anti-ZIKV agents. [Abstract]2023 Oct 5:258:115620. PMID: 37421888 -
Molecules
Dapoxetine, a Selective Serotonin Reuptake Inhibitor, Suppresses Zika Virus Infection In Vitro. [Abstract]2023 Dec 17;28(24):8142. PMID: 38138628 -
Viruses
Broad-Spectrum Antiviral Activity of Influenza A Defective Interfering Particles against Respiratory Syncytial, Yellow Fever, and Zika Virus Replication In Vitro. [Abstract]2023 Sep 4;15(9):1872. PMID: 37766278 -
Virology
Marine-derived ascofuranone as a novel inhibitor of Zika virus with therapeutic potential. [Abstract]2026 Sep:622:110972. PMID: 42217947
Solvente y solubilidad
DMSO : ≥ 33 mg/mL (31.19 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.36 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (282 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Poxton IR, et al. Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections. Future Microbiol. 2010 Apr;5(4):539-48. [Content Brief]
[2]. Tannock GW, et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology (Reading). 2010 Nov;156(Pt 11):3354-3359. [Content Brief]
[3]. Ackermann G, Löffler B, Adler D, Rodloff AC. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother. 2004 Jun;48(6):2280-2. [Content Brief]
[4]. Ackermann G, et al. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother. 2004 Jun;48(6):2280-2. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.9451 mL | 4.7257 mL | 9.4514 mL | 23.6286 mL |
| 5 mM | 0.1890 mL | 0.9451 mL | 1.8903 mL | 4.7257 mL | |
| 10 mM | 0.0945 mL | 0.4726 mL | 0.9451 mL | 2.3629 mL | |
| 15 mM | 0.0630 mL | 0.3150 mL | 0.6301 mL | 1.5752 mL | |
| 20 mM | 0.0473 mL | 0.2363 mL | 0.4726 mL | 1.1814 mL | |
| 25 mM | 0.0378 mL | 0.1890 mL | 0.3781 mL | 0.9451 mL | |
| 30 mM | 0.0315 mL | 0.1575 mL | 0.3150 mL | 0.7876 mL |